Mammogen Raises $30 Million in Series A Funding
Mammogen, a company dedicated to improving the detection, diagnosis, and treatment of breast cancer, has successfully secured $30 million in a Series A funding round. The financing was led by a major U.S. public retirement system, marking a significant milestone for the Newport Beach, California-based firm.
Focus on Women's Health
Founded by Marty Keiser, who also serves as Chairman, Mammogen is at the forefront of developing RNA-powered molecular diagnostics aimed at enhancing women's health. The company's approach focuses on creating more predictive tools for early detection of breast cancer, particularly for women with dense breast tissue, through its flagship product, genTRU-breast™. This blood-based molecular assay is designed to facilitate earlier and more accurate diagnoses.
Strategic Use of Funds
The $30 million raised in this Series A round will be strategically allocated to advance Mammogen's clinical programs and expand its commercialization efforts. The funding will support the company's pivotal prospective clinical program, which is crucial for validating the efficacy and reliability of their molecular diagnostics platform.
Industry Context
This funding comes at a time when there is increasing demand for innovative approaches to health diagnostics, driven by regulatory changes surrounding breast density notifications and a growing consumer interest in proactive health management. Mammogen's advancements align with the broader trends in digital health distribution and molecular diagnostics.
Looking Ahead
With this significant capital injection, Mammogen is well-positioned to continue its mission of transforming the landscape of breast cancer diagnostics. The company's efforts are part of a larger movement within the IV BioHoldings ecosystem, which is dedicated to advancing scalable early detection technologies across various disease areas.
Marty Keiser emphasized the importance of this funding round, stating: "This investment enables us to push forward with our mission to provide women with more reliable and earlier detection options, ultimately improving outcomes and saving lives."